Jennifer Sheng

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth

Meletios Α. Dimopoulos, Sagar Lonial, Darrell White et al. · British Journal of Haematology · 2017 · 131 citations · Full text

A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

Yuxiang Ma, Wen‐Feng Fang, Yang Zhang et al. · The Oncologist · 2019 · 47 citations · Full text

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

Kinjal Sanghavi, Jason Zhang, Xiaochen Zhao et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 40 citations · Full text

Oncology, Human Monoclonal Antibody, Pharmacology +14

Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect

Hefei Zhang, Binfeng Xia, Jennifer Sheng et al. · AAPS PharmSciTech · 2014 · 36 citations · Full text

Chemical Engineering, Food Effect, Food Analysis +10

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Jason Zhang, Kinjal Sanghavi, Jun Shen et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 33 citations · Full text